Do we have the Evidence to Repurpose Levamisole for Treatment of COVID 19?

(E-pub Ahead of Print)

Author(s): Keshab Mukhopadhyay, Chanchal Kumar Dalai, Ritesh Singh, Shah Newaz Ahmed*, Kushal Banerjee

Journal Name: Current Drug Therapy


Become EABM
Become Reviewer
Call for Editor

Abstract:

The human civilization is reeling under COVID19 pandemic with no promising news of any effective treatment against the infection till date. A number of drugs have been repurposed without any remarkable efficacy. Amidst the crisis, utilising immunomodulators for boosting host immunity to mitigate disease severity and infectivity appears a viable option. In this article, we have explored the contemporary scientific evidence about levamisole for its potential use in COVID 19. Though the primary pharmacological use of the drug is as an anthelminthic, its immunostimulatory action has been shown to increase T-cell function, neutrophilic chemotaxis and immunoglobulin production both in vitro and in vivo. Clinically, the drug has been used with limited success in treatment of herpes and HIV. The potential role of the drug in COVID 19 stems from the fact that the immunostimulant action can initiate a strong immune response and surmount the surreptitious virus which evades host cell immunity. However, great caution has to be exercised in deciding the dose schedule because the drug-disease interaction, especially the fatal hyperimmune response, are unknown and unpredictable. Being a widely available drug, enlisted in WHO List of Essential Medicine, without any major safety issue, the drug is already in clinical trials the world over. As the pandemic continues to ravage mankind with unabated intensity, any favourable outcome is eagerly awaited from the ongoing trials with levamisole and other drugs.

Keywords: Levamisole, COVID 19, Immunomodulator, SARS CoV2.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1574885515999201231204530
Price: $95

Article Metrics

PDF: 2